Cargando…

Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis

PURPOSE: We aimed to identify new predictive biomarkers for cetuximab in first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC). METHODS: The study included patients with KRAS wild-type unresectable liver-limited mCRC treated with chemotherapy with or without cetuxi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Peng, Liang, Chunmin, Ren, Li, Zhu, Dexiang, Feng, Qingyang, Chang, Wenju, He, Guodong, Ye, Lechi, Chen, Jingwen, Lin, Qi, Yi, Tuo, Ji, Meiling, Niu, Zhengchuan, Jian, Mi, Wei, Ye, Xu, Jianmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165607/ https://www.ncbi.nlm.nih.gov/pubmed/30305811 http://dx.doi.org/10.1155/2018/5072987

Ejemplares similares

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
por: Tsai, Hsiang-Lin, et al.
Publicado: (2023)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

High MICB expression as a biomarker for good prognosis of colorectal cancer
por: Feng, Qingyang, et al.
Publicado: (2020)

mCRC: rasante Weiterentwicklung zielgerichteter Therapien
por: Arnheim, Katharina
Publicado: (2022)

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
por: Martini, Giulia, et al.
Publicado: (2023)

Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study
por: Feng, Qingyang, et al.
Publicado: (2016)

Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
por: Putri, Septiara, et al.
Publicado: (2023)

Maximising clinical benefit with adequate patient management beyond the second line in mCRC
por: Argiles, Guillem, et al.
Publicado: (2019)

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials
por: Sebio, A., et al.
Publicado: (2016)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
por: El-Deiry, Wafik S., et al.
Publicado: (2019)

Short-Term and Long-Term Outcomes in Mid and Low Rectal Cancer With Robotic Surgery
por: Chen, Jingwen, et al.
Publicado: (2021)

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
por: Rossi, Luigi, et al.
Publicado: (2013)

The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients
por: Yu, Ping, et al.
Publicado: (2018)

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial
por: Marmorino, Federica, et al.
Publicado: (2019)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022)

Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment
por: Chen, Hong-Hwa, et al.
Publicado: (2021)

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
por: Saif, Muhammad Wasif
Publicado: (2013)

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
por: Borelli, Beatrice, et al.
Publicado: (2022)

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib
por: Pommier, A J C, et al.
Publicado: (2014)

Tumor Response to Irinotecan is Associated with IL-10 Expression Level in Metastatic Colorectal Cancer-Results from mCRC Biomarker Study
por: Chang, Jinjia, et al.
Publicado: (2020)

Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study
por: Chang, Jinjia, et al.
Publicado: (2019)

Differences in clinical characteristics and mutational pattern between synchronous and metachronous colorectal liver metastases
por: Zheng, Peng, et al.
Publicado: (2018)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
por: Kurreck, A., et al.
Publicado: (2020)

Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC)
por: Tysarowski, Andrzej, et al.
Publicado: (2018)

Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature
por: Guo, Sheng, et al.
Publicado: (2016)

Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC
por: Hebart, Holger, et al.
Publicado: (2019)

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)
por: Song, Bo, et al.
Publicado: (2023)

Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306
por: Modest, Dominik Paul, et al.
Publicado: (2020)

Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
por: Bahl, Ankur, et al.
Publicado: (2020)

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
por: Zhang, Yiyi, et al.
Publicado: (2021)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

Timing of Hepatectomy for Resectable Synchronous Colorectal Liver Metastases: For Whom Simultaneous Resection Is More Suitable - A Meta-Analysis
por: Feng, Qingyang, et al.
Publicado: (2014)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview
por: Martín-Richard, Marta, et al.
Publicado: (2021)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
por: Schulz, Martin S., et al.
Publicado: (2022)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
por: Scarabel, Lucia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_itbl0gcp4ojdug7q9kavvkq6td